- Report
- April 2023
- 147 Pages
Global
From €4443EUR$4,949USD£3,784GBP
- Report
- April 2023
- 147 Pages
Global
From €4443EUR$4,949USD£3,784GBP
- Report
- April 2023
- 500 Pages
Global
From €2918EUR$3,250USD£2,485GBP
- Report
- October 2022
- 300 Pages
Global
From €3547EUR$3,950USD£3,020GBP
- Report
- January 2022
- 60 Pages
Global
From €3547EUR$3,950USD£3,020GBP
- Report
- January 2022
- 60 Pages
Global
From €3547EUR$3,950USD£3,020GBP
- Report
- September 2023
- 138 Pages
Global
From €3995EUR$4,450USD£3,402GBP
- Report
- June 2024
- 200 Pages
Global
From €7138EUR$7,950USD£6,079GBP
- Report
- June 2024
- 200 Pages
Global
From €7138EUR$7,950USD£6,079GBP
- Report
- April 2023
- 200 Pages
Global
From €3547EUR$3,950USD£3,020GBP
- Report
- February 2025
- 85 Pages
India
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- October 2024
- 87 Pages
Spain
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- September 2024
- 82 Pages
Japan
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- August 2024
- 85 Pages
India
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- August 2024
- 82 Pages
Japan
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- June 2024
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- May 2024
- 184 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- May 2024
- 184 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- February 2024
- 170 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- November 2023
- 171 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells.
CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors.
CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more